Synthesis, structure and catalytic activity of xylylene-bridged dipalladium complexes with triazolylidene ligands
作者:Yufeng Du、Beibei Liang、Fenglei Yang、Yanhui Shi、Xiuling Li、Guangsheng Pang、Changsheng Cao
DOI:10.1007/s11243-016-0117-5
日期:2017.4
di-N-heterocyclic carbene (NHC) dipalladiumcomplexes, [PdPyBr2]2(di-NHC) (2a–h), in which di-NHC represents a di-triazolylidene, featuring a 1,4-xylylene spacer between the carbene units, have been prepared from the reactions of the corresponding ditriazolium bromides with PdCl2 and excess NaBr as an additive in the presence of K2CO3 in pyridine. All of the complexes were fully characterized by NMR
Coumarin-substituted 1,2,4-triazole-derived silver(<scp>i</scp>) and gold(<scp>i</scp>) complexes: synthesis, characterization and anticancer studies
作者:Gautam Achar、Shahini C. R.、Siddappa A. Patil、Jan Grzegorz Małecki、Srinivasa Budagumpi
DOI:10.1039/c8nj02927j
日期:——
between the silver atom and different CH modules of NHC ligands. Further, the in vitro anticancer activities of the silver(I) (13–18) and gold(I) (25–30) complexes toward two human-derived cancer cell lines, the breast cancer (MCF 7) and the colon cancer (HT-29) cell lines have been examined by SRB assay. All the silver(I) complexes displayed higher anticancer potentials than their gold(I) counterparts
METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
申请人:Leftheris Katerina
公开号:US20090227567A1
公开(公告)日:2009-09-10
Methods of treating one or more conditions associated with p38 kinase activity are disclosed comprising administering to a patient in need thereof at least one compound having the formula (I):
or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R
3
is hydrogen, methyl, perfluoromethyl, methoxy, halogen, cyano, or NH
2
, preferably methyl, and X, R
1
through R
6
, and Z are as described in the specification. Advantageously the groups -ZR
4
R
5
taken together comprise an —NH-substituted aryl.
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis.
Here, in this study we report the synthesis and characterizations of novel electrolyte based on dicationic salts 1,3-bis(1-alkyl-1,2,4-triazolium)mesitylene bis(tetrafluoroborate). Two cations were linked by mesitylene as spacer. Using H NMR, C NMR, FTIR and RAMAN spectroscopy methods the structural characterization of synthesized salts were done. Cyclic voltammetry, electrochemical impedance spectroscopy